Knowledge Distillery

The objective of this randomised, double blind, placebo controlled trial was to determine if inhaled and intranasal ciclesonide are superior to…

Our highlighted selection of Covid-related randomised double-blinded placebo-controlled trials from the scientific press for January 2022

Our highlighted selection of Covid-related randomised double-blinded placebo-controlled trials from the scientific press for February 2022

The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein in a…

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2.

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an…

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020.

Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are…

High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19.

The emergence of SARS-CoV-2 variants threatens progress toward control of the Covid-19 pandemic.

LY-CoV555, a neutralising monoclonal antibody, has been associated with a decrease in viral load and frequency of hospitalisations or emergency…

Recent data suggest that complications and death from COVID-19 may be related to high viral loads.